---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-157307"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:42:32.316257+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics prices $140M public offering of common stock and pre-funded warrants

## Summary
- Gross proceeds of ~$140M from 22.99M shares at $2.00/share and 47.01M pre-funded warrants at $1.9999 each.
- Net proceeds estimated at $134.7M after underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to 10.5M additional shares.
- Proceeds for general corporate purposes; existing cash plus offering expected to fund operations into 2026.
- Offering closed May 31 for shares and June 1 for warrants; Morgan Stanley and Wedbush lead.

## SEC filing metadata
- accession: 0001193125-23-157307
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/0001193125-23-157307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/d476076d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-157307
- JSON: https://secwatch.observer/filing/0001193125-23-157307.json
- Plain text: https://secwatch.observer/filing/0001193125-23-157307.txt

## Key facts
- Material Agreements
  TScan Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives (effective 2023-05-25).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives
  - Effective: 2023-05-25
  source text: On May 25, 2023, TScan Therapeutics, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC and Wedbush Securities Inc., as representatives (the “ Representatives ”) of the underwriters named therein
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157307/0001193125-23-157307-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.